U.S. Food and Drug Administration Approves Bristol Myers Squibb…
WEB3 days ago — PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium...
FDA Approves the First New Schizophrenia Drug in Decades
WEB2 days ago — Lenkowsky says Bristol Myers Squibb is conducting a trial studying Cobenfy in combination with dopamine-based medications that will yield results in about a year.
U.S. Food and Drug Administration Approves Bristol Myers Squibb…
WEB3 days ago — PRINCETON, N.J., September 27, 2024 -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline...
FDA Approves Drug with New Mechanism of Action for Treatment …
WEB4 days ago — For Immediate Release: September 26, 2024. Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of...
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia …
WEB3 days ago — Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions with the serious mental disorder.
First new type of treatment for schizophrenia in decades - NPR
WEB2 days ago — Steve Belkowitz/Bristol Myers Squibb. For the first time in decades, the Food and Drug Administration has approved a new type of drug for schizophrenia. The twice-a-day pill to be marketed by...
FDA approves Bristol Myers Squibb's schizophrenia drug
WEB4 days ago — Bristol Myers Squibb expects the twice-daily pill, which will be sold under the brand name Cobenfy, to be available in late October, executives told CNBC. The drug is a badly needed new option...
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb ...
WEB2 days ago — On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers...
Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult ...
WEB3 days ago — (RTTNews) - Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium chloride), an oral medication for the treatment of...
FDA approves Bristol Myers Squibb's new schizophrenia drug
WEB2 days ago — The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated schizophrenia drug, Cobenfy. It’s the first novel treatment for the ...
- Some results have been removed
Skip to content